NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Merck Sharp & Dohme LLC
Cedars-Sinai Medical Center
Dana-Farber Cancer Institute
University of California, San Francisco
Seagen Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hummingbird Bioscience
Merck Sharp & Dohme LLC
Xencor, Inc.
Mayo Clinic
MedSIR
Intensity Therapeutics, Inc.
Dana-Farber Cancer Institute
RAPT Therapeutics, Inc.
Merck Sharp & Dohme LLC
Sellas Life Sciences Group
Eli Lilly and Company
Astellas Pharma Inc
The Methodist Hospital Research Institute
HiberCell, Inc.
Eli Lilly and Company
Celldex Therapeutics
City of Hope Medical Center
Genexine, Inc.
Mayo Clinic
Corvus Pharmaceuticals, Inc.
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Roswell Park Cancer Institute
HiberCell, Inc.
West German Study Group
Fate Therapeutics
Xencor, Inc.
Evelo Biosciences, Inc.
Azienda Ospedaliero-Universitaria di Modena
Tesaro, Inc.
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Eisai Inc.
Incyte Corporation
Incyte Corporation
Syndax Pharmaceuticals
Merck Sharp & Dohme LLC
Centre Leon Berard
Universitaire Ziekenhuizen KU Leuven
Institut fuer Frauengesundheit
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC